Navigation Links
Vermillion Reports Financial Results for the Third Quarter 2010
Date:11/11/2010

vide for more favorable payments terms.  As the diagnostic industry leader, Quest Diagnostics is well positioned to continue to help us drive growth for the test with its installed physician client base.  We look forward to building upon the success to date of our combined efforts to drive steady growth in adoption of OVA1.  The 74% quarterly increase in the number of OVA1 tests performed reinforces the value proposition within the clinical community and reflects the success of our sales and marketing initiatives.  However, given the time to implement these initiatives and a modification to our selling model, we are revising our 2010 guidance to 5,000-5,500 OVA1 tests performed," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.  "The early indicators in the fourth quarter remain encouraging and we are confident in our ability to capture the long-term market opportunity."

Based on calculating revenue under the 2005 agreement with Quest Diagnostics, total revenues for the third quarter of 2010 were $413,000 compared to none for the third quarter of 2009 and $344,000 for the second quarter of 2010.  Revenues for the third quarter of 2010 included $114,000 from product sales of OVA1 and $299,000 of license revenue related to the Company's achievement of certain milestones under the Strategic Alliance Agreement with Quest Diagnostics. As of September 30, 2010, the Company's cash and short-term investments totaled $25.3 million.  The Company utilized $3.3 million in cash and cash equivalents during the third quarter and confirms previous guidance of $3-$4 million cash utilization during the fourth quarter.

Total operating expenses increased in the third quarter of 2010 to $4.0 million from $0.7 million in the same period last year.  Operating expenses increased to $11.2 million for the first nine months of 2010, compared to $3.9 million in the same period in the previous year.  These
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vermillion Receives Award From the Society of Gynecologic Oncologists
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
5. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
6. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
7. Vermillion Announces the Reappointment of Officers and Confirmation of Director
8. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
9. Vermillion Announces $43.05 Million Private Placement of Common Stock
10. Vermillion Files Plan of Reorganization
11. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), ... on cardiac and vascular surgery, announced today that it ... of Vice President, Research and Development; and David P. ... Market Development Surgical Adhesives and Starch Medical Relations.  Dr. ...
... LOUIS, Jan. 4, 2012 Express Scripts now provides ... HealthBridge Pharma & Biotech services. CuraScript, a wholly owned ... suite of services, will be among a limited number ... EYLEA (aflibercept) Injection was approved by the ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5Express Scripts HealthBridge Pharma & Biotech to Provide Specialty Pharmacy and Specialty Distribution Services for EYLEA™ (aflibercept) Injection 2
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... solutions and creators of CMaps Analytics, announced a new location analytics designer for ... professionals to create a wide range of maps experiences in the cloud and ...
(Date:8/27/2015)... ... August 27, 2015 , ... An inventor from Gibertsville, Pa., knows how knees ... against each other while I’m trying to sleep," he said, "so I decided that ... easy-to-use, ergonomic BTKG BED TIME KNEE GUARD helps a user get a better sleep ...
(Date:8/27/2015)... ... 27, 2015 , ... Doctors in the US, the UK and Switzerland say ... especially if given when cells are in the stage known as autophagy. Surviving Mesothelioma ... full article. , Cancer investigators with the University of California, the University of ...
(Date:8/27/2015)... ... August 27, 2015 , ... Generate fully customizable three dimensional ... within Final Cut Pro X. , With ProGeo Refraction, a FCPX Plugin ... do. Users can generate fully customizable three dimensional geometric shape refraction all within Final ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... After conducting ... Smith, Ephraim McDowell Health in Danville, Ky., has hired Burt Piper, as ... leadership experience, Piper will assume his new duties on September 28. , “Burt is ...
Breaking Medicine News(10 mins):Health News:CMaps Analytics Announces New Location Intelligence Integration for SAP Lumira 2Health News:New Research Unveils Potential Method for Improved Response to Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:Announcing a New FCPX Plugin, ProGeo Refraction from Pixel Film Studios. 2Health News:Ephraim McDowell Health Hires New Chief Operating Officer 2Health News:Ephraim McDowell Health Hires New Chief Operating Officer 3
... of actual resveratrol plus 95% OPCs ... and three ... manufacturer,Renaissance Health Publishing, LLC, is disappointed and confused as to ... of Revatrol, and calls on the for-profit laboratory,to remove the ...
... often be the smarter choice, study suggests , MONDAY, Nov. ... symptoms of throat infection, surgery to remove the tonsils is ... watching and waiting to see if symptoms resolve, a Dutch ... University Medical Center Utrecht compared 151 children, ages 2 to ...
... McCandliss, a psychologist at the Sackler Institute for Developmental ... Weill Cornell Medical College, has received a commendation by ... of a Presidential Early Career Award for Scientists and ... by the U.S. government for outstanding scientists and engineers ...
... new article appearing in American Journal of Transplantation describes ... of organ rejection in kidney transplants. The technique, which ... examining DNA sequences, defines how major causes of organ ... behavior. The study is the first to show how ...
... Booker, II, CPA, Presented with Charles Kopke,Medal ... Nov. 19 The American,Diabetes Association (ADA), ... fight against diabetes, announced today that G. ... Arkansas, received the,Association,s prestigious Charles Kopke Medal ...
... an,important step toward protecting patient access to essential ... Fracture Prevention and,Osteoporosis Testing Act of 2007," sponsored ... a reversal of drastic Medicare cuts,to DXA (dual ... the gold standard for measuring bone mass to ...
Cached Medicine News:Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 2Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 3Health News:Tonsillectomy Not Always Cost-Effective for Kids' Throat Woes 2Health News:White House awards Weill Cornell's Bruce McCandliss highest honor for early career scientists 2Health News:Breakthrough in organ rejection diagnosis examines gene behavior 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 3Health News:Congress Moves to Protect Bone Health 2